文献速递慢性肾脏病水电解质与酸碱

托伐普坦治疗ADPKD患者的尿路成石风险谱分析

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-06-11

多变量混合效应模型显示,托伐普坦与草酸钙、透钙磷石和尿酸相对过饱和度降低相关,同时尿枸橼酸和尿钙排泄升高。结论认为托伐普坦治疗与ADPKD患者尿路成石风险谱显著改善相关。

要点

  • 托伐普坦与草酸钙、透钙磷石和尿酸相对过饱和度降低独立相关
  • 托伐普坦与尿枸橼酸及尿钙排泄升高、净酸排泄降低相关
  • 提示托伐普坦可能降低ADPKD患者肾结石风险,但需进一步验证

核心结论

  • 托伐普坦治疗与ADPKD患者尿路成石风险谱显著改善相关。

研究设计与样本

  • Bern ADPKD注册队列的前瞻性观察性研究分析,共纳入125例参与者(38例使用托伐普坦、87例未使用)。
  • 采用未调整及多变量混合效应线性回归模型,调整年龄、性别、体重指数、eGFR、净酸排泄和身高校正总肾脏体积。

主要发现

  • 多变量分析中,托伐普坦与草酸钙相对过饱和度降低相关(差值-0.56;95%CI,-0.82至-0.3;P<0.001)。
  • 托伐普坦与透钙磷石相对过饱和度降低相关(-0.33;95%CI,-0.54至-0.11;P=0.004)、与尿酸相对过饱和度降低相关(-0.62;95%CI,-0.88至-0.37;P<0.001)。
  • 托伐普坦与尿枸橼酸升高相关(0.25 mmol/mmol肌酐/天;95%CI,0.05至0.46;P=0.02)、与尿钙升高相关(0.31 mmol/mmol肌酐/天;95%CI,0.09至0.53;P=0.006)。
  • 托伐普坦与净酸排泄降低相关(-0.54 mEq/mmol肌酐/天;95%CI,-0.90至-0.17;P=0.004)、与净胃肠道碱吸收升高相关(0.57 mEq/mmol肌酐/天;95%CI,0.26至0.88;P<0.001)。

临床怎么用

  • 对接受托伐普坦治疗的ADPKD患者,可关注其尿路成石风险谱的改善趋势,但仍需结合个体情况评估肾结石风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity. Recently, Tolvaptan has been introduced for the treatment of ADPKD, but whether it is associated with alterations of the urinary lithogenic risk profile remains unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an analysis of participants enrolled in the Bern ADPKD registry, a prospective observational cohort study. Twenty-four-hour urine analyses were performed at baseline and then at yearly follow-ups. Relative supersaturation ratios for calcium oxalate, brushite, and uric acid were calculated with the program EQUIL2. Unadjusted and multivariable mixed-effects linear regression models, adjusted for age, sex, body mass index, eGFR, net acid excretion, and height-adjusted total kidney volume, were used to assess the association of Tolvaptan with urinary parameters relevant for kidney stone formation. The maximum individual follow-up time was 3 years, median follow-up time 1.9 years, and cumulative follow-up time 169 years. RESULTS: In total, 125 participants (38 with and 87 without Tolvaptan treatment) were included in the analysis. In multivariable analysis, Tolvaptan treatment was associated [adjusted estimate of the difference between Tolvaptan and no Tolvaptan; 95% confidence interval (CI)] with lower urine relative supersaturation ratios for calcium oxalate (-0.56; 95% CI, -0.82 to -0.3; P<0.001), brushite (-0.33; 95% CI, -0.54 to -0.11; P=0.004), and uric acid (-0.62; 95% CI, -0.88 to -0.37; P<0.001), and with higher urine citrate in mmol/mmol creatinine per day (0.25; 95% CI, 0.05 to 0.46; P=0.02) and calcium in mmol/mmol creatinine per day (0.31; 95% CI, 0.09 to 0.53; P=0.006) excretion. In addition, Tolvaptan treatment was associated with lower net acid excretion in mEq/mmol creatinine per day (-0.54; 95% CI, -0.90 to -0.17; P=0.004) and higher net gastrointestinal alkali absorption in mEq/mmol creatinine per day (0.57; 95% CI, 0.26 to 0.88; P<0.001). CONCLUSIONS: Tolvaptan treatment is associated with a significantly improved urinary lithogenic risk profile in patients with ADPKD.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bargagli M, Dhayat NA, Anderegg M, et al. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. Clin J Am Soc Nephrol. 2020. PMID: 32527945. doi:10.2215/CJN.13861119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。